Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

Cancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific precision therapies. Druggable driver oncogenes, identified by molecular analyses, are present in only a subset of patients. Functional profiling of primary tumor cells could circumvent these limitations, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzella, Gabriele, Schreck, Leonie D., Breunis, Willemijn B., Molenaar, Jan, Merks, Hans, Barr, Frederic G., Sun, Wenyue, Römmele, Michaela, Zhang, Luduo, Tchinda, Joelle, Ngo, Quy A., Bode, Peter, Delattre, Olivier, Surdez, Didier, Rekhi, Bharat, Niggli, Felix K., Schäfer, Beat W., Wachtel, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492191/
https://www.ncbi.nlm.nih.gov/pubmed/32934208
http://dx.doi.org/10.1038/s41467-020-18388-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492191/
https://www.ncbi.nlm.nih.gov/pubmed/32934208
http://dx.doi.org/10.1038/s41467-020-18388-7

Ejemplares similares